Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 27 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/18/2005 First Published: 7/1/1998


1.		Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI, Pharmaceutical / Industry				RPCI-DS-97-29 ZENECA-9238IL/0021, NCI-G98-1412

Last Modified: 5/28/2003 First Published: 2/1/2001


2.		Phase III Randomized Neoadjuvant Study of ICI 182780 in Women With Stage I or II Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Any age				Other				EORTC-10963 BIG-EORTC-10963, NCT00010153


3.		The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				Pharmaceutical / Industry				9238IL/0048 EFECT, NCT00065325


4.		Comparison of Fulvestrant (FASLODEX™) 250 mg and 500mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				D6997C00002 CONFIRM, NCT00099437


5.		Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				No age specified				Pharmaceutical / Industry				D6997L00002 9238SW/0001, FACT, NCT00256698


6.		Faslodex Advanced Breast Cancer Local Chinese Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				D6997L00004 NCT00327769

Last Modified: 10/30/2008 First Published: 12/1/2000


7.		Phase II Study of Fulvestrant in Patients With Newly Recurrent, Persistent, or Metastatic Endometrial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				Not specified				NCI				GOG-0188 NCT00006903

Last Modified: 3/8/2006 First Published: 3/1/2001


8.		Phase II Study of Fulvestrant (ICI 182780) in Women With Metastatic Breast Cancer Who Have Failed Aromatase Inhibitor Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCCTG-N0032 N0032, NCT00012025

Last Modified: 6/10/2008 First Published: 3/24/2003


9.		Phase II Randomized Study of Anastrozole and Gefitinib Versus Fulvestrant and Gefitinib in Postmenopausal Women With Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				ECOG-4101 E4101, NCT00057941

Last Modified: 4/30/2008 First Published: 4/23/2004


10.		Phase II Study of Tipifarnib and Fulvestrant as Second-Line Therapy in Postmenopausal Women With Hormone Receptor-Positive Inoperable Locally Advanced or Metastatic Breast Cancer With Progressive Disease After Prior First-Line Endocrine Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				AECM-0104-085 6205, NCI-6205, NCT00082810

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute